Posted by Michael Wonder on 12 Aug 2024
Sandoz receives FDA approval for Enzeevu (aflibercept-abzv), further strengthening US biosimilar position
12 August 2024 - Enzeevu (aflibercept-abzv) approved to treat neovascular age-related macular degeneration.
Sandoz today announced that the US FDA has approved Enzeevu (aflibercept-abzv) 2 mg vial kit and pre-filled syringe for intravitreal injection.
